Dapagliflozin Use in Liver Cirrhosis

Evidence-Based Recommendations

• The European Association for the Study of the Liver (EASL) guidelines recommend SGLT2 inhibitors, including dapagliflozin, as preferred pharmacological options for treating type 2 diabetes in compensated cirrhosis, with a Child-Pugh score of A or B, and a weak recommendation with consensus-level evidence (LoE 4) for Child-Pugh class B cirrhosis 1
• The EASL-EASD-EASO guidelines specifically list dapagliflozin alongside empagliflozin as first-line agents for diabetic patients with compensated cirrhosis (F4 stage), with a focus on individual patient assessment and monitoring 1
• Insulin is the preferred glucose-lowering agent in decompensated cirrhosis, requiring careful monitoring to avoid hypoglycemia, as recommended by the EASL guidelines 1
• The American Diabetes Association and the European Association for the Study of Diabetes (EASD) suggest that metformin can be used in compensated cirrhosis with eGFR >30 mL/min, but is absolutely contraindicated in decompensated cirrhosis due to lactic acidosis risk, with a recommendation to use alternative agents such as GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) in Child-Pugh class A cirrhosis 1
• The European Society of Cardiology (ESC) notes that while SGLT2 inhibitors are proven safe in heart failure, cirrhosis presents unique pharmacodynamic challenges, including baseline coagulopathy and altered drug metabolism, and recommends caution when using dapagliflozin in patients with cirrhosis 2

Dapagliflozin Use in Cirrhosis

Guideline-Based Recommendations

• The European Association for the Study of the Liver (EASL) guidelines recommend dapagliflozin can be used in patients with Child-Pugh class A and B cirrhosis, but should be avoided in Child-Pugh class C cirrhosis, requiring careful monitoring for acute kidney injury and infections 3
• The EASL-EASD-EASO guidelines specifically list SGLT2 inhibitors, including dapagliflozin, as preferred pharmacological options for treating type 2 diabetes in patients with compensated cirrhosis 3
• Dapagliflozin can be used with caution in Child-Pugh class B cirrhosis according to EASL guidelines, representing a weak recommendation with consensus-level evidence, indicating the need for close monitoring 3
• Insulin therapy is the preferred glucose-lowering agent in Child-Pugh class C cirrhosis, as recommended by the EASL and Journal of Hepatology guidelines 3, 4

Alternative Glucose-Lowering Agents

• The EASL guidelines recommend metformin can be used in compensated cirrhosis with eGFR >30 mL/min, but contraindicated in decompensated cirrhosis due to lactic acidosis risk 3, 4
• GLP-1 receptor agonists, such as semaglutide and liraglutide, are safe in Child-Pugh class A cirrhosis, but should be avoided in decompensated cirrhosis, as per the EASL guidelines 3
• Insulin is the preferred agent in decompensated cirrhosis, though requires careful monitoring to avoid hypoglycemia, as recommended by the EASL and Journal of Hepatology guidelines 3, 4